- Report
- March 2025
- 92 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 510 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- October 2024
- 199 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- December 2024
- 88 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- November 2023
- 185 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Book
- July 2021
- 392 Pages
- Book
- October 2023
Global
- Book
- February 2023
Global

The Neurobiology market is a subset of the Central Nervous System Drugs market, which focuses on the development of treatments for neurological disorders. These treatments are designed to target the underlying causes of neurological diseases, such as genetic mutations, environmental factors, and lifestyle choices. Neurobiology research is focused on understanding the molecular and cellular mechanisms of neurological diseases, as well as developing new treatments and therapies.
The Neurobiology market is highly competitive, with many companies investing in research and development to create new treatments and therapies. Companies in this market are focused on developing treatments for a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. These companies are also investing in the development of new technologies, such as gene therapy and stem cell therapy, to improve the effectiveness of treatments.
Some of the major companies in the Neurobiology market include AbbVie, AstraZeneca, Biogen, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are actively investing in research and development to create new treatments and therapies for neurological disorders. Show Less Read more